INFOBANK

TREATMENTS

The COVID-19 pandemic has been unusual in that very little attention was paid to treatments – patients were often told to go home and return only when symptoms are severe, which could be too late for a successful intervention.

The reality of increasing ‘break-through’ infections after vaccination emphasizes the importance of making early treatment readily available to all, irrespective of vaccination status.

PANDA is not a medical organisation and as such does not endorse any specific drugs or treatment protocols. However, PANDA supports the prioritizing of evidence-based preventative (prophylactic) and early treatment of high-risk groups. There are cheap, safe and effective treatments available to reduce COVID-19 mortality. The studies listed below are for your information only. Please consult with your physician for any medical advice.

AVAILABLE TREATMENTS FOR COVID-19

Pathophysical Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection 

“Therapeutic approaches based on these principles include 1) reduction of reinoculation, 2) combination antiviral therapy, 3) immunomodulation, 4) antiplatelet/antithrombotic therapy, and 5) administration of oxygen, monitoring, and telemedicine.” (McCullough, 2020)

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)

“The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness.”

“A multipronged therapeutic approach includes 1) adjuvant nutraceuticals [supplements and vitamins ], 2) combination intracellular anti-infective therapy [to reduce the multiplication of the virus], 3) inhaled/oral corticosteroids [to treat inflammation], 4) antiplatelet agents/anticoagulants [to treat blood clots], 5) supportive care including supplemental oxygen, monitoring, and telemedicine.” (McCullough et al., 2020)

Early ambulatory multidrug therapy reduces hospitalization and death in high-risk patients with SARS-CoV-2 (COVID-19)

“our early ambulatory treatment regimen was associated with estimated 87.6% and 74.9% reductions in hospitalization and death respectively,”

“Prompt ambulatory treatment should be offered to high-risk patients with COVID-19 instead of watchful watching and late-stage hospitalization for salvage therapies.” (Procter et al., 2021)

SARS-CoV-2 infection and the COVID-19 pandemic: a call to action for therapy and interventions to resolve the crisis of hospitalization, death, and handle the aftermath

“This population [high-risk patients] should be our highest priority and should be tended to with patient treatment guides, immediate access to research protocols, and engagement with physicians either by telemedicine or in person who are familiar with the signals of benefit and the safety information available for these commonly prescribed drugs [19]. Access to monoclonal antibodies available under Emergency Use Authorization should be ensured and featured by emergency departments, urgent care clinics, and nursing homes at the point of care where high-risk patients receive a positive SARS-CoV-2 result” (McCullough & Vijay, 2021)

Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19

“Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials [Ivermectin taken preventatively prior to possible infection] report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin.” (Kory et al., 2021)

Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis and trial sequential analysis to inform clinical guidelines

“Low-certainty evidence found ivermectin prophylaxis reduced COVID-19 infection by an average 86%”

“Meta-analysis of 15 trials found ivermectin reduced risk of death compared with no ivermectin” 

“Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.” (Bryant et al., 2021)

Consult with the Early Covid Care Experts

You can learn about the history, safety and current usage of effective drug treatments for COVID-19, and find COVID-expert doctors who are available either in person or by telemedicine to provide expert outpatient, early treatment for COVID patients.

FURTHER RESOURCES FOR DOCTORS

A Guide to Home-Based COVID Treatment Step-By-Step Doctors’ Plan That Could Save Your Life

(Orient & Vliet, 2021) by the Association of American Physicians and Surgeons.

The BIRD Recommendation on the Use of Ivermectin for COVID-19

(British Ivermectin Recommendation Development, 2021)

More resources:

HCQ

ALSO SEE:

DO REPURPOSED TREATMENTS PROVIDE A VIABLE PATH TO ENDING THE COVID-19 PANDEMIC?

Not prioritizing investigation of affordable options that could potentially have saved lives is an abrogation of responsibility and a betrayal by the WHO. At the very least, a new emphasis on large-scale serious trials of repurposed treatments, while allowing sensible use of what are highly safe medicines, is warranted.